Related Experiment Videos
Anticonvulsant hypersensitivity syndrome with fatal outcome.
Nuria Romero Maldonado1, Javier Sendra Tello, Eduardo Raboso Garcia-Baquero
1Department of Dermatology, Hospital Ramón y Cajal, Carretera de Colmenar, Kilometro 9,100, 28034 Madrid, Spain.
European Journal of Dermatology : EJD
|October 9, 2002
Summary
Anticonvulsant hypersensitivity syndrome, a severe drug reaction, can be fatal, especially with radiotherapy. Early diagnosis and awareness of cross-reactivity are crucial for managing patients on these medications.
Area of Science:
- Pharmacology
- Toxicology
- Oncology
Background:
- Anticonvulsant hypersensitivity syndrome (AHS) is a severe, multisystemic drug reaction.
- It is associated with aromatic anticonvulsants like phenytoin, phenobarbital, and carbamazepine.
- Concomitant radiotherapy may exacerbate AHS, increasing severity.
Observation:
- A case of AHS with toxic epidermal necrolysis (TEN) and fatal outcome is presented.
- The patient received cranial irradiation and aromatic anticonvulsants for seizure prophylaxis.
- This highlights a severe adverse drug reaction in a specific clinical context.
Findings:
- Aromatic anticonvulsants, via arene oxide metabolites, are implicated in AHS.
- The syndrome presents with fever, rash, lymphadenopathy, hypertransaminasemia, and eosinophilia.
- Concurrent radiotherapy significantly increases the aggressiveness and risk of fatal outcomes in AHS.
Implications:
- Emphasizes the critical need for early diagnosis of anticonvulsant hypersensitivity syndrome.
- Highlights the importance of understanding cross-reactivity among aromatic anticonvulsants.
- Stresses the need to carefully weigh the benefits of seizure prophylaxis against risks in brain tumor patients undergoing radiotherapy.